Related Experiment Video
Updated: Apr 30, 2026
Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
Published on: June 20, 2025
Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis
1Sixth Pulmonary Department, Sotiria Hospital for Thoracic Diseases, Athens, Greece. idimit@hotmail.com.
Abstract:
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease with no clear etiology and few therapeutic options. Growth factors that act as mediators in the development of this disease might be important therapeutic targets. Nintedanib is a triple-tyrosine kinase inhibitor and a potent antagonist of growth factors such as platelet-derived growth factor, vascular endothelial growth factor, and basic fibroblast growth factor, and it is currently evaluated in clinical trials as a potential IPF therapy. Treatment with nintedanib may slow decline in lung function, decrease the frequency of exacerbations, and improve quality of life in subjects with IPF. This observation, together with extensive safety and pharmacokinetic data from studies of nintedanib in malignancy, led the way for the clinical development of this drug in IPF. Observations from clinical trials, together with the preclinical data, suggest that nintedanib may become an important therapeutic option for individuals with IPF. High-dose nintedanib improved the quality of life, slowed the progression of lung fibrosis and the decline of lung function, and reduced the rate of exacerbations in individuals with mild and moderate IPF. This is a short review based on the available data (September 2013) on nintedanib.
Insights
Nintedanib, a tyrosine kinase inhibitor, shows promise for treating idiopathic pulmonary fibrosis (IPF). Clinical trials suggest it can slow lung function decline and reduce exacerbations in IPF patients.
Area of Science:
- Pulmonology
- Pharmacology
- Fibrotic Lung Diseases
Background:
- Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with limited treatment options.
- Growth factors are implicated in IPF pathogenesis, presenting potential therapeutic targets.
- Nintedanib, a triple-tyrosine kinase inhibitor, targets key growth factors involved in fibrosis.
Purpose of the Study:
- To review the therapeutic potential of nintedanib for idiopathic pulmonary fibrosis (IPF).
- To evaluate nintedanib's efficacy in slowing disease progression and improving patient outcomes in IPF.
Main Methods:
- Review of available clinical trial data and preclinical studies on nintedanib in IPF (as of September 2013).
- Assessment of nintedanib's safety and pharmacokinetic profile, drawing from oncology studies.
- Evaluation of nintedanib's impact on lung function decline, exacerbation rates, and quality of life.
Main Results:
- Nintedanib demonstrated potential to slow the decline in lung function in IPF patients.
- Treatment with nintedanib was associated with a reduced frequency of IPF exacerbations.
- High-dose nintedanib improved quality of life and slowed lung fibrosis progression in mild to moderate IPF.
Conclusions:
- Nintedanib shows promise as a significant therapeutic option for individuals with IPF.
- The drug's efficacy in slowing disease progression and improving quality of life supports its clinical development in IPF.
- Further clinical evaluation is warranted based on existing safety and efficacy data.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:23Chronic Obstructive Pulmonary Disease I: Introduction